ArticleHuman genetics2011
Biobanking and international interoperability: samples.
Article in Human genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Developing Policy for the Healthy Life Trajectories Initiative: Going from National to International.Biopreservation and biobanking · 2023Article
- Integrating research infrastructures into infectious diseases surveillance operations: Focus on biobanks.Biosafety and health · 2022Article
- Regulations and Norms for Reuse of Residual Clinical Biospecimens and Health Data.Western journal of nursing research · 2022Review
- From biobank and data silos into a data commons: convergence to support translational medicine.Journal of translational medicine · 2021Article
- Towards Harmonized Biobanking for Biomonitoring: A Comparison of Human Biomonitoring-Related and Clinical Biorepositories.Biopreservation and biobanking · 2020Article
- The Experience of Establishing Data Sharing & Linkage Platforms for Administrative, Research and Community-Service Data.International journal of population data science · 2019Article
- Obstacles to Widening Biosample Research.Science and engineering ethics · 2019Article
- Sustainability in Biobanking.Methods in molecular biology (Clifton, N.J.) · 2019Article
- [Preanalytics and biobanking : Influence of preanalytical factors on tissue sample quality].Der Pathologe · 2018Review
- Biobanks in the Era of Digital Medicine.Clinical pharmacology and therapeutics · 2018Article
- Legal & ethical compliance when sharing biospecimen.Briefings in functional genomics · 2018Article
- A critical analysis of cancer biobank practices in relation to biospecimen quality.Biophysical reviews · 2015Review
- How to build an integrated biobank: the Washington University Translational Cardiovascular Biobank & Repository experience.Clinical and translational science · 2013Article
- Consent for use of clinical leftover biosample: a survey among Chinese patients and the general public.PloS one · 2012Article
- Bridging consent: from toll bridges to lift bridges?BMC medical genomics · 2011Article
- The art and science of biobanking.Human genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In terms of sample exchange, international collaborations between biobanks, or between biobanks and their research partners, have two important aspects. First, the donors' consent usually implies that the scope and purpose of any sample transfer to third parties is subject to major constraints. Since the legal, ethical and political framework of biobanking may differ substantially, even between countries of comparable jurisdictional systems, general rules for the international sharing of biomaterial are difficult, if not impossible, to define. Issues of uncertainty include the right to transfer the material, the scope of research allowed, and intellectual property rights. Since suitable means of international law enforcement may not be available in the context of biobanking, collaborators are advised to clarify any residual uncertainty by means of bilateral contracts, for example, in the form of material transfer agreements. Second, biobank partners may rightly expect that the biomaterial they receive for further analysis attains a certain level of quality. This implies that a biobank has to implement stringent quality control measures covering, in addition to the material transfer itself, the whole process of material acquisition, transport, pre-analytical handling and storage. Again, it may be advisable for biobank partners to claim contractual warranties for the type and quality of the biomaterial they wish to acquire.
Indexed as
Identifiers
21761135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.